title: Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines.
abstract: The immunogenicity of a yeast-derived recombinant hepatitis B virus (HBV) vaccine containing surface antigen (S) and selected preS1 and preS2 sequences (S-L*) was compared with that of a vaccine containing S alone (Engerix-B) in 32 healthy adults with a previous history of poor response (anti-HBs < 10 mIU ml-1) after at least three consecutive monthly doses of hepatitis B vaccines. The poor responders were randomized to receive three additional 20-microgram doses of either S-L* or Engerix-B in a double-blind fashion according to a 0-, 1-, 2-month schedule. In vivo humoral and in vitro lymphoproliferative responses to the S and preS regions were monitored. Although the addition of the selected preS sequences to S did not enhance the in vivo humoral anti-HBs response, the administration of the three additional vaccine doses, irrespective of their preS content, induced seroprotective anti-HBs levels in most vaccinees (29/32, 91%). In vitro proliferative responses to HBV surface antigens were only observed in subjects displaying anti-HBs titers > 1000 mIU ml-1 after the third additional vaccine dose.
authors.affiliation: Department of Clinical Chemistry, University of Gent, Belgium. Geert.Lerouxroels@rug.ac.be
authors.forename: G
authors.initials: G
authors.lastname: Leroux-Roels
authors.forename: I
authors.initials: I
authors.lastname: Desombere
authors.forename: L
authors.initials: L
authors.lastname: Cobbaut
authors.forename: M A
authors.initials: MA
authors.lastname: Petit
authors.forename: P
authors.initials: P
authors.lastname: Desmons
authors.forename: P
authors.initials: P
authors.lastname: Hauser
authors.forename: A
authors.initials: A
authors.lastname: Delem
authors.forename: D
authors.initials: D
authors.lastname: De Grave
authors.forename: A
authors.initials: A
authors.lastname: Safary
mesh_terms: D000328:Adult; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D004311:Double-Blind Method; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011498:Protein Precursors / Q000276:immunology*
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D011498:Protein Precursors; C050806:presurface protein 1, hepatitis B surface antigen; C050807:presurface protein 2, hepatitis B surface antigen